Hycor Demonstrates Noveos Immunoanalyzer that Sets New Standards to Limit Impact of Interference
By LabMedica International staff writers Posted on 29 Sep 2021 |
Hycor Biomedical (Garden Grove, CA, USA) demonstrated its new NOVEOS immunoanalyzer at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.
Every year, the global laboratory medicine community comes together at AACC to collaborate and create system-wide changes that improve patient outcomes and enhance the quality of life for all. The exhibition provides a platform to connect with the industry leaders making ground-breaking advancements in laboratory medicine, including clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, and lab management.
The NOVEOS immunoanalyzer has been designed to overcome challenges confronting laboratories routinely testing for allergen-specific IgE to aid in the diagnosis of allergic diseases. The system was designed to address common issues laboratorians face with current technologies by offering several innovative features, including a significant reduction in sample size, reduced blood-based interferences, less variability within allergen lots, increased accuracy and improved walk-away time for laboratory technicians.
NOVEOS IgE chemiluminescent immunoassay uses streptavidin-coated magnetic beads, a biotinylated capture allergen, serum sample and monoclonal anti-human IgE antibody. Only 4µL of patient sample volume is required which can be especially important in pediatric and geriatric sampling where it may be more difficult to retrieve larger samples. On-board reagents supply sufficient capacity for up to eight hours of continuous testing. This eliminates the need to continuously replenish materials throughout a typical work day. It allows maximum walk away time for laboratory technicians by allowing up to 75 tests per specific allergen and up to 140 allergens on the system at any time.
Many of the unrefined extracts that are used in skin-prick testing and competitive allergy assays generate less reliable patient results due to their complexity. As the allergen industry moves to more highly enriched or standardized extracts, the NOVEOS system has incorporated these materials to provide more consistent and accurate results. The advanced micro-particle technology limits interference from: Biotin, IgG / IgG4, and solid-phase related cross-reactive carbohydrate determinant (CCD). NOVEOS offers high sensitivity, excellent low-end precision and operates for up to 13 hours of true walk-away capability.
Related Links:
Hycor Biomedical
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms